Dihydrofolate reductase (DHFR), a core enzyme of folate metabolism, plays a crucial role in the biosynthesis of purines and thymidylate for cell proliferation and growth in both prokaryotic and eukaryotic cells. However, the development of new DHFR inhibitors is challenging due to the limited number of scaffolds available for drug development. Hence, we designed and synthesized a new class of DHFR inhibitors with a 1,3-diamino-7-pyrrol[3,2-]quinazoline derivative (PQD) structure bearing condensed rings. Compound exhibited therapeutic effects on mouse models of systemic infection and thigh infection caused by methicillin-resistant (MRSA) ATCC 43300. Moreover, methyl-modified PQD compound showed a strong efficacy in a murine model of breast cancer, which was better than the effects of taxol. The findings showcased in this study highlight the promising capabilities of novel DHFR inhibitors in addressing bacterial infections as well as breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.3c00891 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dihydrofolate reductase inhibitory potential of 1H-indole-based-meldrum linked 1H-1,2,3-triazoles as new anticancer derivatives: In-vitro and in-silico studies.
Eur J Med Chem
February 2025
Natural and Medical Sciences Research Center, University of Nizwa, P.O. Box 33, 616, Nizwa, Oman. Electronic address:
In this present work, we describe the syntheses of a new series of 32 1H-indole-based-meldrum linked 1H-1,2,3-triazole derivatives (2-13, 15a-15f, 16a-16f, 17a-17f and 19a, 19b, 20a), which constitute a new class of 1H-1,2,3-triazoles. Compounds 15a-15f, 16a-16f, 17a-17f have been prepared by employing "click" reactions between substituted 1H-indole-based meldrum alkynes (11, 12 and 13) and substituted aromatic azides (14a-14f) in the presence of copper iodide (CuI) and Hünig's base. Then, the synthesis of compounds 19, 20 through decomposition of meldrum moiety.
View Article and Find Full Text PDFMolecular modeling, synthesis and biological evaluation of caffeic acid based Dihydrofolate reductase inhibitors.
BMC Chem
December 2024
Laboratory of Preservation Technology and Enzyme Inhibition Studies, Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India.
Dihydrofolate reductase (DHFR) is an enzyme that plays a crucial role in folate metabolism, which is essential for cell growth and division. DHFR has been identified as a molecular target for numerous diseases due to its significance in various biological processes. DHFR inhibitors can disrupt folate metabolism by inhibiting DHFR, leading to the inhibition of cell growth.
View Article and Find Full Text PDFRecent Cutting-Edge Designing Strategies for Mtb-DHFR Inhibitors as Antitubercular Agents.
Chem Biol Drug Des
December 2024
Department of Pharmaceutical Chemistry, ISF College of Pharmacy, Moga, Punjab, India.
Tuberculosis (TB) is an obstinate and infectious disease requiring a relatively longer treatment duration than other bacterial infections. The current treatment regime is prolonged and cumbersome, with adverse effects, often leading to nonadherence. The upsurge in TB's multidrug-resistant and extensively drug-resistant strains with evolved resistance to existing drugs has compounded the problems.
View Article and Find Full Text PDFSynthesis and Antimicrobial Evaluation of New 1,2,4-Triazolo[1,5-]pyrimidine-Based Derivatives as Dual Inhibitors of Bacterial DNA Gyrase and DHFR.
ACS Omega
November 2024
Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Boys), Al-Azhar University, Assiut 71524, Egypt.
A series of 1,2,4-triazolo[1,5-]pyrimidine-based derivatives were developed and prepared by reacting chalcones - with 3-phenyl-1,2,4-triazole-5-amine (). The novel compounds were analyzed using several spectroscopic techniques, and their antimicrobial efficacies against six pathogens (Gram-negative, Gram-positive, and fungi) were tested. Most of the tested compounds exhibited significant antimicrobial activity compared to ciprofloxacin and fluconazole.
View Article and Find Full Text PDFSynthesis, enzyme inhibition, and docking studies of new schiff bases of disalicylic acid methylene-based derivatives as dual-target antibacterial agents.
Front Chem
November 2024
Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
Article Synopsis
- * Compounds made from disalicylic acid methylene/Schiff bases were tested and found to be effective antibacterial agents, showing better or comparable performance to the antibiotic Ciprofloxacin against various bacteria.
- * Specific compounds exhibited lower minimum inhibitory concentrations (MIC) than Ciprofloxacin and showed strong inhibition of DNA gyrase and DHFR, highlighting their potential as new treatment options for antibiotic-resistant infections.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!